Subhasish Baral
Overview
Explore the profile of Subhasish Baral including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waghmare A, Krantz E, Baral S, Vasquez E, Loeffelholz T, Chung E, et al.
J Infect Dis
. 2020 Jul;
226(2):278-286.
PMID: 32710762
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic demonstrates the need for accurate and convenient approaches to diagnose and therapeutically monitor respiratory viral infections. We demonstrated that self-sampling with...
2.
Waghmare A, Krantz E, Baral S, Vasquez E, Loeffelholz T, Chung E, et al.
medRxiv
. 2020 Jun;
PMID: 32511581
The SARS-CoV-2 pandemic demonstrates the need for accurate and convenient approaches to diagnose and therapeutically monitor respiratory viral infections. We demonstrated that self-sampling with foam swabs at home is well-tolerated...
3.
Baral S, Antia R, Dixit N
Proc Natl Acad Sci U S A
. 2019 Aug;
116(35):17393-17398.
PMID: 31413198
Some viral infections culminate in very different outcomes in different individuals. They can be rapidly cleared in some, cause persistent infection in others, and cause mortality from immunopathology in yet...
4.
Baral S, Raja R, Sen P, Dixit N
Wiley Interdiscip Rev Syst Biol Med
. 2019 Feb;
11(4):e1446.
PMID: 30811096
The CD8 T cell response is critical to the control of viral infections. Yet, defining the CD8 T cell response to viral infections quantitatively has been a challenge. Following antigen...
5.
Raja R, Baral S, Dixit N
Immunol Rev
. 2018 Aug;
285(1):55-71.
PMID: 30129199
The advent of powerful direct-acting antiviral agents (DAAs) has revolutionized the treatment of hepatitis C. DAAs cure nearly all patients with short duration, oral treatments. Significant efforts are now underway...
6.
Baral S, Roy R, Dixit N
Immunol Cell Biol
. 2018 May;
96(9):969-980.
PMID: 29744934
A fraction of chronic hepatitis C patients treated with direct-acting antivirals (DAAs) achieved sustained virological responses (SVR), or cure, despite having detectable viremia at the end of treatment (EOT). This...